Healthcare >> CEO Interviews >> June 1, 2009
MARTIN E. SCHMIEG, President and Chief Executive Officer of Nuvilex, Inc., has
over 20 years of experience launching and building businesses in the medical
device, biotechnology and life sciences industries. As CEO of Freedom-2 Inc., a
development stage company pursuing a novel medical device technology injected
permanent and biodegradable polymers for cosmetic and medical therapeutic and
diagnostic applications he drove all aspects of company development. Prior to
Freedom-2, Mr. Schmieg repeatedly transitioned companies with innovative
technologies to successful product-based enterprises while increasing valuation
through his proven financial management, negotiation skills and aggressive
fundraising capabilities. Working with companies such as Sirna Therapeutics,
Advanced Bionics and Cytometrics, he raised capital in excess of $55 million for
one enterprise, raised the market capitalization of another from zero to $200
million, and was the financial architect of a $4.2 billion sale of a third
company to a Fortune 500 company. Mr. Schmieg's executive experience spans
operating functions including finance and management to marketing and business
strategy. He holds a BS in Business Administration from LaSalle University and
is a Guest Lecturer at the MIT Sloan School of Management and at the University
of Pennsylvania's School of Engineering, Arts and Sciences. He is a Mentor at
the Port of Technology, University City Science Center's business development
incubator. He is a CPA in Pennsylvania. Profile
Mr. Schmieg: Nuvilex (OTCBB: NVLX) is the combination of two companies,
eFoodSafety.com (OTCBB:EFSF) and Freedom2 Inc., a private
